U.S. markets open in 5 hours 43 minutes
  • S&P Futures

    3,835.25
    +8.00 (+0.21%)
     
  • Dow Futures

    31,101.00
    +40.00 (+0.13%)
     
  • Nasdaq Futures

    11,651.25
    +40.00 (+0.34%)
     
  • Russell 2000 Futures

    1,729.60
    +1.10 (+0.06%)
     
  • Crude Oil

    109.70
    +1.27 (+1.17%)
     
  • Gold

    1,807.30
    +5.80 (+0.32%)
     
  • Silver

    19.95
    +0.28 (+1.44%)
     
  • EUR/USD

    1.0387
    -0.0037 (-0.35%)
     
  • 10-Yr Bond

    2.8890
    0.0000 (0.00%)
     
  • Vix

    27.37
    -1.34 (-4.67%)
     
  • GBP/USD

    1.2080
    -0.0025 (-0.20%)
     
  • USD/JPY

    136.0750
    +0.4150 (+0.31%)
     
  • BTC-USD

    20,216.29
    +1,109.23 (+5.81%)
     
  • CMC Crypto 200

    439.81
    +19.67 (+4.68%)
     
  • FTSE 100

    7,222.16
    -10.49 (-0.15%)
     
  • Nikkei 225

    26,423.47
    +269.66 (+1.03%)
     

UPDATE 1-Sanofi's Dupixent gets U.S. approval to treat eczema in young children

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

(Adds details about drug, approval)

June 7 (Reuters) - The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron Pharmaceuticals Inc's anti-inflammation drug Dupixent to treat eczema in young children, the two companies said on Tuesday.

Dupixent is now the first approved treatment for moderate-to-severe eczema in young children, Sanofi and Regeneron said.

Sanofi records global net product sales of Dupixent, while Regeneron gets a share of profit or loss from the drug.

The approval for the drug in children aged 6 months to 5 years was based on data from a late-stage study in which Dupixent improved skin clearance and reduced severity of eczema when used with a corticosteroids cream.

The drug works by blocking the inflammation-causing IL-4 and IL-13 proteins involved in the body's immune response that the companies believe to be underlying reasons for a number of inflammatory conditions.

Dupixent, with 2021 sales of 5.25 billion euros, accounted for 13.9% of Sanofi's revenue, making it the Paris-listed company's best-selling product.

Dupixent is already approved for treating a range of diseases in adult populations in the United States, including eczema or atopic dermatitis, severe asthma and an allergic inflammation of the esophagus.

Atopic dermatitis, or eczema, is a chronic skin condition that causes inflammation and irritation of skin. It affects about 30% of the U.S. population, mostly children and adolescents, according to the National Institute of Allergy and Infectious Diseases. https://www.niaid.nih.gov/diseases-conditions/eczema-atopic-dermatitis (Reporting by Bhanvi Satija and Leroy Leo in Bengaluru; Editing by Sriraj Kalluvila)